30881332|t|Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis.
30881332|a|Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with limited treatment options. Despite decades of therapeutic development, only two modestly efficacious disease-modifying drugs-riluzole and edaravone-are available to ALS patients. Biomarkers that can facilitate ALS diagnosis, aid in prognosis, and measure drug pharmacodynamics are needed to accelerate therapeutic development for patients with ALS. Positron emission tomography (PET) imaging has promise as a biomarker for ALS because it permits visualization of central nervous system (CNS) pathology in individuals living with ALS. The availability of PET radioligands that target a variety of potential pathophysiological mechanisms-including cerebral metabolism, neuroinflammation, neuronal dysfunction, and oxidative stress-has enabled dynamic interrogation of molecular changes in ALS, in both natural history studies and human clinical trials. PET imaging has potential as a diagnostic biomarker that can establish upper motor neuron (UMN) pathology in ALS patients without overt UMN symptoms, as a prognostic biomarker that might help stratify patients for clinical trials, and as a pharmacodynamic biomarker that measures the biological effect of investigational drugs in the brain and spinal cord. In this Review, we discuss progress made with 30 years of PET imaging studies in ALS and consider future research needed to establish PET imaging biomarkers for ALS therapeutic development.
30881332	62	91	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
30881332	93	122	Amyotrophic lateral sclerosis	Disease	MESH:D000690
30881332	124	127	ALS	Disease	MESH:D000690
30881332	140	166	neurodegenerative disorder	Disease	MESH:D019636
30881332	297	305	riluzole	Chemical	MESH:D019782
30881332	310	319	edaravone	Chemical	MESH:D000077553
30881332	337	340	ALS	Disease	MESH:D000690
30881332	341	349	patients	Species	9606
30881332	382	385	ALS	Disease	MESH:D000690
30881332	502	510	patients	Species	9606
30881332	516	519	ALS	Disease	MESH:D000690
30881332	595	598	ALS	Disease	MESH:D000690
30881332	701	704	ALS	Disease	MESH:D000690
30881332	839	856	neuroinflammation	Disease	MESH:D000090862
30881332	858	878	neuronal dysfunction	Disease	MESH:D009461
30881332	959	962	ALS	Disease	MESH:D000690
30881332	1000	1005	human	Species	9606
30881332	1106	1112	neuron	Disease	MESH:D009410
30881332	1114	1117	UMN	Disease	MESH:D016472
30881332	1132	1135	ALS	Disease	MESH:D000690
30881332	1136	1144	patients	Species	9606
30881332	1159	1171	UMN symptoms	Disease	MESH:D012816
30881332	1224	1232	patients	Species	9606
30881332	1461	1464	ALS	Disease	MESH:D000690
30881332	1541	1544	ALS	Disease	MESH:D000690
30881332	Negative_Correlation	MESH:D000077553	MESH:D000690
30881332	Negative_Correlation	MESH:D019782	MESH:D000690

